Forest Laboratories announced the launch of Namenda XR (memantine HCl) extended-release capsules, the once-daily formulation of Namenda. Namenda XR is indicated for the treatment of moderate-to-severe Alzheimer’s dementia.
Namenda XR, an NMDA antagonist, is thought to exert its therapeutic effect through its action as a low-to-moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.
Namenda XR is available in 7mg and 21mg tablets in 30-count bottles, and 14mg and 28mg tablets in 30- and 90-count bottles. Namenda XR is also available as a titration pack that contains 28 capsules (7x7mg, 7x14mg, 7x21mg, 7x28mg).
For more information call (800) 678-1605 or visit NamendaXR.com.